A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer
文摘
TMX-101 0.4% is a novel intravesical formulation of imiquimod, a toll-like receptor agonist. In this phase-2 study of patients with CIS, TMX-101 had an excellent safety profile. Activity was suggested by significant increases in urinary cytokines including IL-18. A total of 2 patients demonstrated a complete response 6 weeks following treatment.